223785-92-0

Usage

Uses

Used in Pharmaceutical Industry:
4-ISOTHIOCYANATO-N,N-DIMETHYLBENZENESULFONAMIDE is used as a building block for the synthesis of CYM 9484 (D461045), a selective small molecule neuropeptide Y Y2 receptor antagonist. 4-ISOTHIOCYANATO-N,N-DIMETHYLBENZENESULFONAMIDE plays a crucial role in the development of potential therapeutic agents targeting the neuropeptide Y Y2 receptor, which may have applications in treating various medical conditions.

Upstream product

• 463-71-8 thiophosgene 
• 1709-59-7 4-amino-N,N-dimethylbenzenesulphonamide 

Downstream Products

• 443799-44-8 4-(5-amino-1H-[1,2,4]triazol-3-ylamino)-N,N-dimethylbenzenesulfonamide 
• 1533434-85-3 (Z)-methyl N'-cyano-N-(4-(N,N-dimethylsulfamoyl)phenyl)carbamimidothioate 
• 1383479-19-3 C₂₇H₃₀FN₃O₃S₂ 
• 1383479-17-1 C₂₅H₂₉N₃O₄S₂ 
• 1383479-16-0 C₂₅H₂₉N₃O₃S₃ 
• 1383479-15-9 CHEMB⁽³⁰¹⁾L₂₀₇₉ 
• 1383479-14-8 C₂₆H₃₀N₄O₃S₂ 
• 1383479-21-7 CHEMB⁽³⁰¹⁾L₂₀₈₅ 

Relevant academic research and scientific papers

TRIAZOLE COMPOUNDS AS ANTIVIRALS

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

Substituted 4-amino-thiazol-2-yl compounds as cyclin-dependent kinase inhibitors

Pharmaceutical compositions containing effective amounts of CDK-inhibiting diaminothiazole compounds of the following formula (where R1and R2are as defined in the specification) or their salts, or prodrugs or active metabolites of such compounds or salts, are useful for treating disorders and diseases such as cancer: In preferred embodiments, R1and R2are independently unsubstituted or substituted carbocyclic or heterocyclic aryl ring structures. Compounds where R2is ortho-substituted aryl are especially potent inhibitors of CDKs such as CDK4.

4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases

This invention is directed to aminothiazole compounds of formula (I) wherein R1 is a substituted or unsubstituted group selected from : C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl; (C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol, thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; or a pharmaceutically acceptable salt of a compound of formula (I), or a prodrug or pharmaceutically active metabolite of a compound of formula (I) or pharmaceutically acceptable salt thereof, for inhibiting cyclin-dependent kinases (CDKs), such as CDK1, CDK2, CDK4, and CDK6. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.